| 101 |
23714533 | The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. | 2013 |
4 |
| 102 |
23967177 | The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. | 2013 |
5 |
| 103 |
23998902 | The E3 ubiquitin ligase TRAF2 can contribute to TNF-α resistance in FLT3-ITD-positive AML cells. | 2013 Nov |
2 |
| 104 |
24002496 | Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. | 2013 Oct 10 |
2 |
| 105 |
24070241 | The role of quizartinib in the treatment of acute myeloid leukemia. | 2013 Dec |
5 |
| 106 |
22504184 | Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. | 2012 Apr 15 |
3 |
| 107 |
22875611 | The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. | 2012 Nov |
1 |
| 108 |
23012328 | Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. | 2012 Nov 15 |
3 |
| 109 |
21895538 | The clinical development of FLT3 inhibitors in acute myeloid leukemia. | 2011 Oct |
2 |
| 110 |
19654408 | AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). | 2009 Oct 1 |
1 |
| 111 |
19754199 | Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. | 2009 Dec 10 |
2 |